Spectral Medical Inc. Share Price

Equities

EDT

CA8475771033

Pharmaceuticals

Market Closed - Toronto S.E. 01:29:10 27/04/2024 am IST 5-day change 1st Jan Change
0.48 CAD +6.67% Intraday chart for Spectral Medical Inc. +9.09% +12.94%

Financials

Sales 2024 * 1.4M 1.02M 85.38M Sales 2025 * 2.5M 1.83M 152M Capitalization 134M 98.03M 8.18B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 95.8 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 53.6 x
P/E ratio 2024 *
-12 x
P/E ratio 2025 *
-24 x
Employees 29
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.49%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Spectral Medical Inc.

1 day+6.67%
1 week+9.09%
Current month+2.13%
1 month+3.23%
3 months-5.88%
6 months+41.18%
Current year+12.94%
More quotes
1 week
0.41
Extreme 0.41
0.49
1 month
0.41
Extreme 0.405
0.49
Current year
0.39
Extreme 0.385
0.67
1 year
0.23
Extreme 0.225
0.67
3 years
0.15
Extreme 0.15
0.67
5 years
0.15
Extreme 0.15
0.85
10 years
0.15
Extreme 0.15
2.07
More quotes
Managers TitleAgeSince
Chief Executive Officer - 02/19/02
Chairman - 01/01/01
Chief Tech/Sci/R&D Officer - 01/21/01
Members of the board TitleAgeSince
Chairman - 01/01/01
Director/Board Member 67 01/08/01
Director/Board Member 69 12/21/12
More insiders
Date Price Change Volume
26/24/26 0.48 +6.67% 56,923
25/24/25 0.45 +5.88% 26,100
24/24/24 0.425 -3.41% 6,500
23/24/23 0.44 +2.33% 12,068
22/24/22 0.43 -2.27% 14,910

Delayed Quote Toronto S.E., April 27, 2024 at 01:29 am IST

More quotes
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX has been on the market in many countries outside the United States and has been used in more than 340,000 patients to date. It is engaged in the development of biochemical markers for the clinical syndrome known as septic shock. It is also continuing its legacy business of manufacturing and selling certain reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.48 CAD
Average target price
1.8 CAD
Spread / Average Target
+275.00%
Consensus